Drug profile · INN
copper
PARAGARD T 380A
- US status
- approved
- Patents linked
- 8
- News articles
- 0
Quick answer
copper (PARAGARD T 380A) is an FDA-listed pharmaceutical active ingredient. Route of administration: intrauterine. Current US regulatory status: approved.
Key facts
Related patents
Search patents →-
US 12241902
Probes for detection of copper
granted -
US 12173306
Codon-optimized reduced-size ATP7A CDNA and uses for treatment of copper transport disorders
granted -
US 12121580
Antibacterial photodynamic therapy using copper-cysteamine nanoparticles
granted -
US 11000568
Means and methods for treating copper-related diseases
granted -
US 11000502
Antimicrobial compositions comprising copper-hydroxypyrone complexes
granted -
US 10988778
Codon-optimized reduced-size ATP7A cDNA and uses for treatment of copper transport disorders
granted -
US 10383940
Copper-cysteamine and methods of use
granted -
US 10080379
Zinc and copper fortifying composition, a hydrating supplement, and process for preparing the same
granted
Frequently asked questions
What is copper?
copper (PARAGARD T 380A) is an FDA-listed pharmaceutical active ingredient. Route of administration: intrauterine. Current US regulatory status: approved.
What is the brand name for copper?
PARAGARD T 380A is a marketed brand name for copper. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of copper?
copper has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.